- Home
- AES vs LEGN Comparison
AES vs LEGN Comparison
Compare AES & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AES
- LEGN
- Stock Information
- Founded
- AES 1981
- LEGN 2014
- Country
- AES United States
- LEGN United States
- Employees
- AES N/A
- LEGN N/A
- Industry
- AES Electric Utilities: Central
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- AES Utilities
- LEGN Health Care
- Exchange
- AES Nasdaq
- LEGN Nasdaq
- Market Cap
- AES 7.1B
- LEGN 6.7B
- IPO Year
- AES 1991
- LEGN 2020
- Fundamental
- Price
- AES $12.88
- LEGN $33.11
- Analyst Decision
- AES Hold
- LEGN Strong Buy
- Analyst Count
- AES 8
- LEGN 12
- Target Price
- AES $13.29
- LEGN $73.36
- AVG Volume (30 Days)
- AES 8.9M
- LEGN 1.1M
- Earning Date
- AES 10-30-2025
- LEGN 11-11-2025
- Dividend Yield
- AES 5.46%
- LEGN N/A
- EPS Growth
- AES 8.40
- LEGN N/A
- EPS
- AES 1.28
- LEGN N/A
- Revenue
- AES $12,032,000,000.00
- LEGN $796,838,000.00
- Revenue This Year
- AES $2.44
- LEGN $70.75
- Revenue Next Year
- AES $4.21
- LEGN $52.47
- P/E Ratio
- AES $9.98
- LEGN N/A
- Revenue Growth
- AES N/A
- LEGN 74.75
- 52 Week Low
- AES $9.46
- LEGN $27.34
- 52 Week High
- AES $20.30
- LEGN $52.31
- Technical
- Relative Strength Index (RSI)
- AES 46.52
- LEGN 36.16
- Support Level
- AES $12.56
- LEGN $33.20
- Resistance Level
- AES $13.44
- LEGN $34.71
- Average True Range (ATR)
- AES 0.32
- LEGN 1.22
- MACD
- AES -0.08
- LEGN -0.09
- Stochastic Oscillator
- AES 40.53
- LEGN 10.96
About AES The AES Corporation
AES is a global power company that operates in 15 countries. Its generation portfolio as of year-end 2023 totals over 35 gigawatts, including renewable energy (53%), gas (27%), coal (18%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.